39,543 Becton, Dickinson and Company $BDX Shares Bought by James Hambro & Partners LLP

James Hambro & Partners LLP grew its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 13.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 335,229 shares of the medical instruments supplier’s stock after purchasing an additional 39,543 shares during the period. Becton, Dickinson and Company comprises about 2.1% of James Hambro & Partners LLP’s portfolio, making the stock its 19th biggest position. James Hambro & Partners LLP’s holdings in Becton, Dickinson and Company were worth $60,026,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. SHP Wealth Management purchased a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at approximately $26,000. Maryland Capital Advisors Inc. increased its stake in Becton, Dickinson and Company by 13,900.0% during the 3rd quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 139 shares during the period. Meeder Asset Management Inc. increased its stake in Becton, Dickinson and Company by 152.2% during the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 102 shares during the period. Bayban purchased a new stake in Becton, Dickinson and Company during the 4th quarter worth approximately $36,000. Finally, Main Street Group LTD acquired a new stake in Becton, Dickinson and Company during the 1st quarter worth approximately $29,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Evercore set a $180.00 price target on shares of Becton, Dickinson and Company in a research report on Monday, July 6th. Piper Sandler upped their price objective on Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Bank of America increased their price objective on Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Monday, August 31st. Weiss Ratings upgraded Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, September 28th. Finally, UBS Group began coverage on Becton, Dickinson and Company in a report on Tuesday, July 28th. They issued a “buy” rating and a $190.00 target price for the company. Seven equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $185.07.

Becton, Dickinson and Company Stock Down 0.5%

Shares of Becton, Dickinson and Company stock traded down $0.87 on Monday, reaching $190.88. 462,204 shares of the company were exchanged, compared to its average volume of 2,460,462. The stock’s 50 day moving average price is $184.03 and its 200-day moving average price is $163.76. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $195.99. The company has a market cap of $52.60 billion, a P/E ratio of 57.47, a price-to-earnings-growth ratio of 12.93 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter last year, the company earned $3.68 earnings per share. The firm’s revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th were given a $1.05 dividend. The ex-dividend date of this dividend was Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is currently 126.51%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of the stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president directly owned 19,720 shares of the company’s stock, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 6,906 shares of company stock valued at $1,265,855. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.